cse lvt

Levitee Labs Acquires Three Specialized Alberta Pharmacies

  • Levitee has completed the acquisition of three pharmacies specialized in filling prescriptions for patients with substance abuse disorders, mental health conditions and chronic pain
  • Revenue for the group of pharmacies has increased 25% in the last 12 months
  • The pharmacies are synergistic with Levitee's other Alberta assets including the recently purchased BlockMD telemedicine platform, and 5 ACT Medical clinics

Levitee Labs Inc. (the " Company " or " Levitee "), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that, effective today, it has completed the acquisition of all the issued and outstanding shares of 2143327 Alberta Ltd., 2144209 Alberta Ltd., and 2017162 Alberta Ltd. (collectively, the " Companies ") for $3,637,528 in cash.

Each of the Companies operates a pharmacy in Alberta specialized in filling prescriptions for medications used to treat people with substance use disorders, mental health conditions and chronic pain. The pharmacies also offer home delivery options to their customers. In the aggregate, the Companies had revenues of approximately $3,000,000 over the past 12 months, with $800,000 in EBITDA. The purchase price represents approximately 4.5x EBITDA on a trailing basis.

"Purchasing these pharmacies was part and parcel to our strategy to be a vertically integrated company focused on substance abuse and chronic conditions," said Pouya Farmand, Chief Executive Officer at Levitee. "In addition to this transaction, we've now closed on the acquisitions of BlockMD, a telemedicine company focused on addiction, and the operating assets of ACT Medical Centres, which operates five addiction clinics in Alberta that collectively conducted over 35,000 visits in the last year. Adding three specialized pharmacies gives us a commanding position to serve Albertans in need, from curating treatment programs on-site or remotely to filling prescriptions and delivering them directly to patients' homes."

"We are excited to add another key cash flowing piece to our portfolio that is synergistic with our other treatment assets," added Ken Osborne, Head of Mergers & Acquisitions at Levitee. "Our team is working hard to identify and vet additional assets in our target verticals that we can bring on and through which we can achieve economies of scale. We are truly excited for what is to come."

About Levitee Labs

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

Further information about the Company is available on its website at .

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting the Company's plans with respect to its newly acquired assets, the Company's overall vision and strategy, Levitee's business plans and proposed products. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Levitee to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. These risks and uncertainties include, but are not limited to, those identified and reported in the Company's public filings under the Company's SEDAR profile at . Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that any such statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

For further information about Levitee, please contact:

Levitee Media Contact

Levitee Investor and Corporate Communications

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer

Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer

Phillips also named President of Altemia & Co., a Lobe Sciences Company

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with sickle cell anemia. Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia. Phillips will report directly to Chairman and Chief Executive Officer Philip J. Young. In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

COMPASS Pathways' key patents upheld by the US Patent and Trademark Office

  • PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).

  • In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to establish that any of the claims of ‘257 Patent and ‘259 Patent are unpatentable.

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation, announced today that the US Patent Trial and Appeal Board (PTAB) reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the Company's phase 3 clinical trials. The decision can be found on the USPTO website at: https:developer.uspto.govptab-web#searchdocuments?proceedingNumber=PGR2022-00018.

Kabir Nath, COMPASS Pathways Chief Executive Officer, stated, "COMPASS is pleased with the PTAB's decision to uphold two important US patents covering the Company's crystalline psilocybin polymorph A. Patents are a key element of our overall commercial protection of COMP360, which is central to our work in developing innovative treatments for therapeutic areas of significant unmet medical need, including our lead program in treatment-resistant depression."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mike Arnold, founder and CEO of Silo Wellness

Silo Wellness CEO Sees Market Traction for Psychedelic Healing

If recent social media and news trends are any indication, psychedelics-based healing may increasingly be getting into mainstream consciousness, according to Silo Wellness (CSE:SILO,OTCQB:SILFF) CEO and Founder Mike Arnold.

“If you just look at the conversations out in public or on social media, and compare that to news articles about this particular space, about psychedelic healing, you'll see an exponential increase since 2018. And you have more and more people being exposed, which means more and more people are feeling something they haven't felt for a really long time, or maybe ever,” Arnold said.

Silo Wellness offers luxury psychedelic retreats in Jamaica. These retreats are supervised by healthcare practitioners — including a doctorate of nursing and a pharmacologist — who are involved in the process from the beginning of a participant’s journey, Arnold explained.

Keep reading...Show less

COMPASS Pathways' Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her executive responsibilities will be carried forward by the existing executive team.

Together with George Goldsmith and Lars Wilde, Katya co-founded COMPASS Pathways in 2017, determined to bring much needed innovation to the field of mental health care. She helped oversee the growth of COMPASS and provided critical executive leadership to the company both before and after its initial public offering in 2020. During her tenure, she oversaw the development and execution of the groundbreaking phase 2b trial of COMP360 psilocybin for patients with treatment-resistant depression, started and helped build critical functions such as R&D, Digital Health, AI and Machine Learning, and Clinical Care Innovation. She also developed the company's psychological support model and built its network of trained therapists.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference


COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Jefferies Healthcare Conference at 3:30 pm ET on June 8, 2023.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

  • More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support
  • Open label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conducted

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new long-term efficacy data of investigational COMP360 psilocybin in cancer patients with major depressive disorder will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

More than half of the patients (16/28) treated with a single dose of 25mg COMP360 psilocybin with psychological support remained in remission from their depression at 18 months post administration. The investigator-initiated study, led by Manish Agrawal, MD, at Sunstone Therapies , is believed to be the longest study of psilocybin therapy ever conducted.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News